Alzheimer’s Disease, Aduhelm, and The Fear of False Hope

Ryan Townley

I am a father, a husband, a neurologist who specializes in Alzheimer's and other neurodegenerative diseases, a program director at a university, and a clinical researcher. The brain is the most complex thing in the known universe. Views expressed here are my own.

Related Post Roulette

6 Responses

  1. Brandon Berg says:

    Somewhat off-topic, but what’s the situation with trials of fisetin or dasatinib and quercetin to clear out senescent glial cells? Are there any case studies of off-label use for Alzheimer’s or other neurodegenerative diseases?Report

  2. Jaybird says:

    “Because we do not have any medications that modify Alzheimer’s pathophysiology, so why test for it?”

    This is one hell of a perverse incentive.

    If nothing else, I’m glad that this justification against proper diagnosis now has cracks in its armor.Report

  3. Oscar Gordon says:

    In a twist of irony, it may be insurance companies, that provide us with the needed guidance that the FDA failed to provide.

    Don’t worry, I’m sure the media will pillory the insurance companies straight away for putting profits over people.Report

  4. Jenny Riggs says:

    Thank you, Dr. Townley! Your research at the KU Alzheimer’s Research Center inspired me to apply for the AHEAD study in Kansas City, and I will be getting the results of my Amyloid and Tau PET scan on June 16 (my mom’s birthday). I am deeply grateful for the opportunity to participate in this research, and encourage others to join!Report

    • Ryan Townley in reply to Jenny Riggs says:

      Jenny – thank you so much for the comment and we really appreciate your dedication to research to help us try to understand and fight back against this disease!Report